| Dr Veenu Gill, MD | |
|
5620 W Thunderbird Rd, Glendale, AZ 85306-4636 | |
| (602) 795-7256 | |
| (602) 795-7257 |
| Full Name | Dr Veenu Gill |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 17 Years |
| Location | 5620 W Thunderbird Rd, Glendale, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336497189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 50455 (Arizona) | Secondary |
| 207R00000X | Internal Medicine | 50455 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Leading Healthcare Specialist, Pllc | 6002246352 | 12 |
News Archive
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm's proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).
A multi-institutional team of researchers led by Emory University has defined for the first time how metal ions bind to amyloid fibrils in the brain in a way that appears toxic to neurons.
In order to provide the most effective treatments for cancer patients, it is essential to develop methods of sensitive and specific early detection of the disease. A team of scientists from the NIBRT Dublin-Oxford Glycobiology Laboratory at UCD has developed a system which aims to pinpoint potential "biomarkers" of early forms of the disease.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).
› Verified 2 days ago
| Entity Name | Apex Physicians Infectious Diseases Specialists & Travel Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417414368 PECOS PAC ID: 2961744487 Enrollment ID: O20190503000182 |
News Archive
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm's proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).
A multi-institutional team of researchers led by Emory University has defined for the first time how metal ions bind to amyloid fibrils in the brain in a way that appears toxic to neurons.
In order to provide the most effective treatments for cancer patients, it is essential to develop methods of sensitive and specific early detection of the disease. A team of scientists from the NIBRT Dublin-Oxford Glycobiology Laboratory at UCD has developed a system which aims to pinpoint potential "biomarkers" of early forms of the disease.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).
› Verified 2 days ago
| Entity Name | Leading Healthcare Specialist, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497390561 PECOS PAC ID: 6002246352 Enrollment ID: O20200428002292 |
News Archive
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm's proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).
A multi-institutional team of researchers led by Emory University has defined for the first time how metal ions bind to amyloid fibrils in the brain in a way that appears toxic to neurons.
In order to provide the most effective treatments for cancer patients, it is essential to develop methods of sensitive and specific early detection of the disease. A team of scientists from the NIBRT Dublin-Oxford Glycobiology Laboratory at UCD has developed a system which aims to pinpoint potential "biomarkers" of early forms of the disease.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).
› Verified 2 days ago
| Entity Name | Lifeline Hospitalist Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265107478 PECOS PAC ID: 3577961606 Enrollment ID: O20211004003129 |
News Archive
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm's proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).
A multi-institutional team of researchers led by Emory University has defined for the first time how metal ions bind to amyloid fibrils in the brain in a way that appears toxic to neurons.
In order to provide the most effective treatments for cancer patients, it is essential to develop methods of sensitive and specific early detection of the disease. A team of scientists from the NIBRT Dublin-Oxford Glycobiology Laboratory at UCD has developed a system which aims to pinpoint potential "biomarkers" of early forms of the disease.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Veenu Gill, MD 5620 W Thunderbird Rd, Glendale, AZ 85306-4636 Ph: (602) 795-7256 | Dr Veenu Gill, MD 5620 W Thunderbird Rd, Glendale, AZ 85306-4636 Ph: (602) 795-7256 |
News Archive
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm's proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).
A multi-institutional team of researchers led by Emory University has defined for the first time how metal ions bind to amyloid fibrils in the brain in a way that appears toxic to neurons.
In order to provide the most effective treatments for cancer patients, it is essential to develop methods of sensitive and specific early detection of the disease. A team of scientists from the NIBRT Dublin-Oxford Glycobiology Laboratory at UCD has developed a system which aims to pinpoint potential "biomarkers" of early forms of the disease.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).
› Verified 2 days ago
Dr. Stephanie D Martinez Hawthorne, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7701 W Aspera Blvd, Glendale, AZ 85308 Phone: 623-248-2109 Fax: 623-707-4893 | |
Dr. Sanjay B Kulkarni, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2632 | |
Arya John Nikamal, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
David Warfield, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5601 W Eugie Ave Ste 203, Glendale, AZ 85304 Phone: 602-633-3833 Fax: 602-633-3834 | |
Anne Margaret Floyd, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5620 W Thunderbird Rd Ste H3, Glendale, AZ 85306 Phone: 480-994-5012 | |
Dr. Karen Brenda Alonso, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5555 W. Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2632 | |
Dr. Abrar U Khan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5555 W Thunderbird, Banner Thunderbird Medical Center, Glendale, AZ 85306 Phone: 602-865-2627 Fax: 602-865-2631 |